The notices it replaced
- Reissues: PA-20-260 PHS 2020-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 2 steps back: PA-19-272 PHS 2019-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed
- 3 steps back: PA-18-574 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
- 4 steps back: PA-17-302 PHS 2017-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 5 steps back: PA-16-302 PHS 2016-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 6 steps back: PA-15-269 PHS 2015-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 7 steps back: PA-14-071 PHS 2014-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 8 steps back: PA-13-234 Reissue PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 9 steps back: PA-13-088 PHS 2013-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 10 steps back: PA-12-088 PHS 2012-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 11 steps back: PA-11-096 PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 12 steps back: PA-10-050 PHS 2010-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
- 13 steps back: PA-09-080 PHS 2009-02 Omnibus Solicitation of the NIH, CDC, FDA and ACF for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44])
Replaced by PA-22-176.
Who won it before
6,331 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,571,152,904 in first-year total cost, median $276,415.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]284
- Special Emphasis Panel[ZRG1 ETTN-G (12)]236
- Special Emphasis Panel[ZRG1 IMST-H (15)]202
- Special Emphasis Panel[ZRG1 IDM-V (12)]185
- Special Emphasis Panel[ZRG1 IMST-B (12)]179
Most frequent institutions
- EPICYPHER, INC.42
- PHYSICAL SCIENCES, INC42
- AFFINERGY, LLC30
- LYNNTECH, INC.26
- MINNESOTA HEALTHSOLUTIONS CORPORATION24
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | A youth-specific helmet for preventing traumatic brain injury2R44NS119134-03A1 | AVERY, GORDONCECCHI, NICHOLAS JAMES | SAVIOR BRAIN INC., VA | $2,864,855 | ZRG1 |
| 2023 | Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD1R44AG085411-01 | ALWORTH, SAMUEL VFENG, ZHIHUA | ACURASTEM, INC., CA | $1,492,509 | ZRG1 |
| 2023 | A Disease-Modifying Protein Therapeutic for the Treatment of COPD2R44HL149580-02 | PRINCE, CHRISTOPHER LUCAS | VERRA THERAPEUTICS, INC., NY | $1,364,498 | ZRG1 |
| 2023 | Development of a novel peptide therapeutic for traumatic brain injury1R44NS130776-01 | MANN, AMAN | AIVOCODE, LLP, CA | $1,290,957 | ZRG1 |
| 2023 | Novel recombinant sensors to study histone ubiquitin signaling1R44GM149036-01 | SUN, ZU-WEN | EPICYPHER, INC., NC | $1,276,822 | ZRG1 |
| 2023 | Development of a Novel Bone Adhesive Scaffold to Accelerate Bone Regeneration and Improve Ridge Height Maintenance for the Treatment of Patients with Residual Ridge Resorption1R44DE032564-01 | JADIA, RAHULKAY, GEORGE | REVBIO, INC., MA | $1,265,448 | ZRG1 |
| 2023 | Expansion and validation of novel mobile app for guiding home modifications for aging in place2R44AG067804-02 | TENENBAUM, LOUIS | HOMESRENEWED VENTURES LLC, DC | $1,170,977 | ZRG1 |
| 2023 | ViTrack: Wearable, accurate, continuous blood pressure monitor to improve outcomes in hypertensive diseases of pregnancy1R44HL167356-01 | THANIKACHALAM, MOHAN | DYNOCARDIA, INC., MA | $1,168,681 | ZRG1 |
| 2023 | Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis1R44GM149065-01 | REDDY, BOBBY | PRENOSIS, INC., IL | $1,161,624 | ZRG1 |
| 2023 | Development of a high precision and high order DNA counting platform1R44GM149104-01 | SHUM, ELEEN YEE LAM | ENUMERIX, INC., CA | $1,080,705 | ZRG1 |
| 2023 | Platform for the High Throughput Generation and Validation of Affinity Reagents1R44GM148998-01 | WEINER, MICHAEL P | ABBRATECH, INC., CT | $1,080,240 | ZRG1 |
| 2023 | Diagnostic tool for assessment and tracking of microbial load in bloodstream infections1R44AI174578-01 | SINGER, ALON | HELIXBIND, INC., MA | $1,050,000 | ZRG1 |
| 2023 | Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle2R44AI152788-03 | MCDONNELL, MARK E | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,050,000 | ZRG1 |
| 2023 | Rapid, Handheld, Point-of-Care Stool Sample-prep Device for the Extraction and Detection of Nucleic Acid from Diarrheal Pathogens2R44AI155367-02 | KIM, CHANG HEE | GODX, INC., WI | $1,050,000 | ZRG1 |
| 2023 | A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)1R44AI174332-01 | FANGER, GARYFURLAN FREGUIA, CHRISTIAN | RISE THERAPEUTICS, LLC, MD | $1,026,596 | ZRG1 |
| 2023 | Point-of-care diagnostic test for T. cruzi (Chagas) infection2R44AI136172-03A1 | LEVIN, ANDREW E. | KEPHERA DIAGNOSTICS, LLC, MA | $1,020,000 | ZRG1 |
| 2023 | A silicon nanopore membrane blood filter enabling anticoagulant free continuous renal replacement therapy for acute kidney injury2R44DK120242-02A1 | BLAHA, CHARLES | SILICON KIDNEY, LLC, CA | $1,019,979 | ZRG1 |
| 2023 | Scalable single-cell workflow for multiomic analyses of chromatin interactions, accessibility, gene expression and cell surface proteins to unravel mechanisms of cellular diversity1R44GM149103-01 | SCHMITT, ANTHONY | ARIMA GENOMICS, INC., CA | $1,013,363 | ZRG1 |
| 2023 | Non-Clinical Pharmacology of CX-012R44AI106283-06A1 | VID, GALINA | CERAMEDIX HOLDING, LLC, NY | $1,011,743 | ZRG1 |
| 2023 | Quantitative Analysis of Cancer-associated EVs1R44CA272098-01A1 | NOLAN, JOHN P | CELLARCUS BIOSCIENCES INC, CA | $1,008,320 | ZRG1 |
| 2023 | Development of ultra-efficient antibodies for single cell mapping applications1R44AI174357-01 | JOHNSTONE, ANDREA LYNN | EPICYPHER, INC., NC | $1,007,748 | ZRG1 |
| 2023 | Novel Sample Introduction Methodologies for Molecular Rotational Resonance (MRR) Spectroscopy1R44GM146526-01A1 | BLAGOJEVIC, VOISLAV | BRIGHTSPEC, INC., VA | $1,006,315 | ZRG1 |
| 2023 | A state-of-the-art web platform for collaborative, longitudinal genome diagnostics1R44HG012885-01 | WARD, ALISTAIR | FRAMESHIFT LABS, INC., MA | $1,000,930 | ZRG1 |
| 2023 | HaloFilm: a spray-on, re-chargeable, re-applicable antimicrobial coating2R44AI155114-02 | DEMIR, BUKET | HALOMINE, INC., NY | $1,000,000 | ZRG1 |
| 2023 | Enabling Toxoplasma gondii Kinome Directed Drug Discovery2R44AI145502-02 | ZUTSHI, REENA | LUCEOME BIOTECHNOLOGIES, LLC, AZ | $1,000,000 | ZRG1 |
| 2023 | Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies2R44AI155254-04 | BLATTNER, FREDERICK RDARNELL, STEVEN JOSEPHLANDRY, CHARLES F | DNASTAR, INC., WI | $1,000,000 | ZRG1 |
| 2023 | Novel drug combinations for improving survival from acute radiation syndrome when administered 48 hours post- irradiation2R44AI142909-03 | COX, GEORGE NORBERT | BOLDER BIOTECHNOLOGY, INC., CO | $1,000,000 | ZRG1 |
| 2023 | A single antiviral to treat multiple opportunistic infections2R44AI114079-05 | REMISZEWSKI, STACY | EVRYS BIO, LLC, PA | $999,998 | ZRG1 |
| 2023 | ARRAY: A novel polymeric mesh for prophylactic antibiotic protection of cardiac implantable electronic devices1R44HL167315-01 | YU, JIAYI | 21MEDTECH LLC, NC | $999,978 | ZRG1 |
| 2023 | A genetically modified Plasmodium falciparum sporozoite vaccine attenuated at the late-liver stage2R44AI149927-03 | SIM, B. KIM LEE | SANARIA, INC., MD | $999,880 | ZRG1 |
| 2023 | Development of TP-317 in Ulcerative Colitis2R44DK116460-04 | PARKINSON, JOHN | THETIS PHARMACEUTICALS, LLC, CT | $997,635 | ZRG1 |
| 2023 | Development of D6PV- a novel ApoC-II peptide mimetic therapeutic1R44DK135188-01 | DEVALARAJA, MATT | PROTEAN BIO INC., MA | $997,484 | ZRG1 |
| 2023 | SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia2R44HL145948-02 | BRUCKMAN, MICHAEL ARTHUR | HAIMA THERAPEUTICS, LLC, OH | $994,448 | ZRG1 |
| 2023 | Novel hand hygiene product to remove Clostridioides difficile spores1R44AI170313-01A1 | LABIB, MOHAMED E | NOVAFLUX, INC., NJ | $993,963 | ZRG1 |
| 2023 | Humanized monoclonal antibodies to treat mucormycosis2R44AI138904-03A1 | IBRAHIM, ASHRAF S.LAZAR, GARY | VITALEX BIOSCIENCES, LLC, CA | $987,901 | ZRG1 |
| 2023 | Development of an RNA-based anticoagulant and antidote for precise on/off coagulation control during cardiovascular procedures1R44HL167436-01 | KRISSANAPRASIT, ABHICHART | HELIXOMER, INC., NC | $983,573 | ZRG1 |
| 2023 | Functionally Closed Purification and Elution of Untouched Cells using Cleavable Magnetic Beads with Digital Magnetic Sorting1R44GM149063-01 | MURRAY, COLEMAN | FERROLOGIX, INC., CA | $921,412 | ZRG1 |
| 2023 | Beacon-OUD: Behavioral Economic Screening Tool of Opioid Use Disorder for Use in Clinical Practice2R44DA048689-02 | SNIDER, SARAH EMILY | BEAM DIAGNOSTICS, INC., VA | $902,713 | ZRG1 |
| 2023 | Multiplexed Analysis of the Epitranscriptome2R44HG012170-02 | STENGEL, GUDRUN | ALIDA BIOSCIENCES, INC., CA | $865,189 | ZRG1 |
| 2023 | Development of a shelf-stable universal mucosal HA-vaccine for the prevention of influenza1R44AI174337-01 | DAVENPORT, GREGORY | TFF PHARMACEUTICALS, INC., TX | $864,948 | ZRG1 |
| 2023 | Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer1R44CA278078-01 | BROWN, ERIC JGILAD, ORENSIMPKINS, FIONA | APREA THERAPEUTICS, INC., MA | $862,205 | ZRG1 |
| 2023 | A Novel Waveguide to Enable MAS-DNP-NMR in Standard-bore High-field Magnets2R44GM139468-02 | DOTY, FRANCIS DAVID | DOTY SCIENTIFIC, INC., SC | $860,734 | ZRG1 |
| 2023 | Advancing Fetal Assessment during Labor with Transabdominal Fetal Oximetry2R44HD094486-02A1 | RAY, NEIL PADHARIA | RAYDIANT OXIMETRY, INC., CA | $855,675 | ZRG1 |
| 2023 | Field Instrument for Assessment of Arsenic Exposure1R44ES034314-01 | ARGUN, AVNI A | GINER, INC., MA | $845,085 | ZRG1 |
| 2023 | Development of a Colorimetric Sensor for Detection of Cerebrospinal Fluid Leaks1R44NS130769-01 | HU, MIN | DRINKSAVVY, INC., MA | $840,440 | ZRG1 |
| 2023 | MomNet: Development of a Coach-Training Program for an Empirically Supported, Guided ehealth Intervention for Depressed Mothers2R44MH123278-02 | DAVIS, BETSYFEIL, EDWARD GUSTAVSMITH, DAVID RANDOLPH | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $825,964 | ZRG1 |
| 2023 | Scaling Volumetric Imaging, Analysis and Science Communication Using Immersive Virtual Reality2R44MH125238-03 | DORETTO, GIANFRANCOMOREHEAD, MICHAEL DAVIDSPIROU, GEORGE A | ISTOVISR, WV | $798,921 | ZRG1 |
| 2023 | Minimally Invasive High Intensity Therapeutic Ultrasound for the Treatment of Obstructive Hypertrophic Cardiomyopathy1R44HL167428-01 | LEVIN, HOWARD | CORIDEA, LLC, NY | $784,548 | ZRG1 |
| 2023 | Development of a Molecular Diagnostic to Identify Dangerous Intracranial Aneurysms2R44NS115314-02 | POPPENBERG, KERRYTUTINO, VINCENT MATTHEW | NEUROVASCULAR DIAGNOSTICS, INC., NY | $766,944 | ZRG1 |
| 2023 | Preclinical development of ONCT-505, an Androgen Receptor Antagonist and Degrader, as new potential therapeutic for Kennedy's Disease1R44NS130806-01 | KRISHNAN, RAJESH | ONCTERNAL THERAPEUTICS, INC., CA | $753,745 | ZRG1 |
| 2023 | Mitochondrial-Targeted Therapy for Macular Degeneration1R44EY034732-01 | COUSINS, SCOTT WILLIAM | ECLIPSE LIFE SCIENCES, INC., NC | $749,999 | ZRG1 |
| 2023 | Noregen, a regenerative medicine ocular therapeutic2R44EY030807-02 | DRENSER, KIMBERLY | RETINAL SOLUTIONS LLC, MI | $717,783 | ZRG1 |
| 2023 | In vivo high-definition 3D corneal imaging2R44EY029906-02 | CANAVESI, CRISTINA | LIGHTOPTECH CORPORATION, NY | $717,714 | ZRG1 |
| 2023 | Interstitial pressure sensor to detect fluid status1R43HL164166-01A1 | SCHWARTZ, ROBERT | NXT BIOMEDICAL, LLC, CA | $634,926 | ZRG1 |
| 2023 | Novel therapeutic for HPA hyperactivity2R44AA027971-02 | LLOYD, LINDA S | STRESS THERAPEUTICS, INC., CA | $605,405 | ZRG1 |
| 2023 | Toward urinary catheterization with long-term resistance to bacterial colonization2R44DK103398-05 | ZOLOTARSKAYA, OLGA | WYNNVISION, LLC, VA | $514,604 | ZRG1 |
| 2023 | Optimizing virtual hits of human CGAS inhibitors to treat neurodegeneration1R43AG080954-01 | GAN, LISINHA, ANJANA | AETON THERAPEUTICS, INC., CA | $499,540 | ZRG1 |
| 2023 | Development of Novel sgp130-Fc Bioconjugates for TBI1R44NS130780-01 | HASKINS, WILLIAM E | GRYPHON BIO, INC., CA | $484,997 | ZRG1 |
| 2023 | In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease1R43NS127693-01A1 | BEHROUZ, BAHAREHHENDERSON, MICHAEL | VINCERE BIOSCIENCES, INC., MA | $470,514 | ZRG1 |
| 2023 | An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy1R43CA275541-01 | SAXENA, DEEKSHA | LIQUID BIODX LLC, PA | $399,499 | ZRG1 |
| 2023 | High-throughput functional analysis and clinical relevance of all possible variants of a gene1R43HG012537-01A1 | SCHILLER, MARTIN R. | HELIGENICS INC, NV | $398,526 | ZRG1 |
| 2023 | Deep learning methods to accelerate discoveryof drugs targeting gene regulatory proteins1R43GM146472-01A1 | FONDRIE, WILLIAM ELLIS | TALUS BIOSCIENCE, INC., WA | $398,441 | ZRG1 |
| 2023 | Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies1R43CA277958-01 | ZHOU, XIANZHENG | TINKESO THERAPEUTICS INC, NY | $398,040 | ZRG1 |
| 2023 | Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers1R43CA278127-01 | ESPOSITO, MARK | KAYOTHERA INC., NJ | $398,040 | ZRG1 |
| 2023 | Two-Color Near-Infrared Fluorescence Guided Surgery Tools Enabling Simultaneous Cancer Margin and Nerve Visualization during Head and Neck Squamous Cell Carcinoma Resection1R43CA272030-01A1 | BARTH, CONNOR WILLIAM | TRACE BIOSCIENCES INC, OR | $386,211 | ZRG1 |
| 2023 | PRECARE is an innovative and integrated platform designed to improve the developmental surveillance of the baby.1R43HD107740-01A1 | MA, TONY XUYEN | BENTEN TECHNOLOGIES, INC., VA | $385,000 | ZRG1 |
| 2023 | Quantitative Normalization of Spatial Metabolomics for Molecular Signatures of Tissue Heterogeneity1R43GM149044-01 | HEJAZI, LEILAZHANG, GUANSHI | SYGNAMAP, INC., TX | $356,499 | ZRG1 |
| 2023 | Development of a Novel Calcium Channel Therapeutic for the Treatment of Asthma1R43HL167426-01 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $352,030 | ZRG1 |
| 2023 | Development of a sensitive method to measure heparan sulfate 6-O-endosulfatase1R43GM149008-01 | SU, GUOWEI | GLYCAN THERAPEUTICS CORPORATION, NC | $350,000 | ZRG1 |
| 2023 | An early-intervention gene-editing therapeutic for Pulmonary Arterial Hypertension1R43HL167478-01 | JASKULA-RANGA, VINODSUSSAN, THOMAS E | HUNTERIAN MEDICINE LLC, MA | $350,000 | ZRG1 |
| 2023 | Remmie.ai: a deep learning diagnostic assistance engine for ear-nose-throat diseases1R43DC020868-01 | ZHANG, JANE | REMMIE, INC., WA | $349,902 | ZRG1 |
| 2023 | Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia1R43EY034770-01 | MOLOKHIA, SARAH ABDULLA | IVEENA DELIVERY SYSTEMS, INC., UT | $345,000 | ZRG1 |
| 2023 | DEVELOPMENT OF A SALIVARY ASSAY FOR MEASURING PERIODONTAL DISEASE ACTIVITY1R43DE032549-01 | GELLIBOLIAN, ROBERT | CELLECTGEN, INC., CA | $320,606 | ZRG1 |
| 2023 | MagPAD: Magnetic Puncture, Access, and Delivery of Large Bore Devices to the Heart Via the Venous System1R43HL167347-01 | DOHERTY, MARK | MAGPAD, LLC, CA | $308,401 | ZRG1 |
| 2023 | Activity-based regulome profiling for the discovery of covalent transcription factor inhibitors1R44TR004349-01 | FEDERATION, ALEXANDER | TALUS BIOSCIENCE, INC., WA | $307,465 | ZTR1 |
| 2023 | Development of a PCR assay for quantitative detection of HBV cccDNA1R43AI174349-01 | LIN, SELENA | JBS SCIENCE, INC., PA | $306,500 | ZRG1 |
| 2023 | PA21259, SBIR, Phase I, Development of a rapid, direct from blood, phenotypic antimicrobial susceptibility assay1R43IP001234-01 | DAMICO, LORENZO | AINCOBIO LLC, NY | $306,500 | ZRG1 |
| 2023 | Precision Guidance of Resuscitation and Deresuscitation in Sepsis1R43GM149094-01 | FELDSCHUH, JONATHAN | DAXOR CORPORATION, TN | $305,000 | ZRG1 |
| 2023 | Development of a novel disease-modifying glycan therapeutic for early at-home intervention of acute vaso-occlusive crisis in sickle cell disease1R44HL167473-01 | JOHN PADERI, JOHN PADERI JOHN PADERI | IHP THERAPEUTICS, INC., CA | $301,480 | ZRG1 |
| 2023 | Multi-Omics And Synbio Enabled Discovery Of Antifungal Fernene Triterpenes1R43AI174407-01 | KELLEHER, NEIL LKELLER, NANCY PMEAD, DAVID ALAN | VARIGEN BIOSCIENCES CORPORATION, WI | $300,000 | ZRG1 |
| 2023 | Novel antimicrobials in fighting carbapenem-resistant Klebsiella pneumoniae1R43AI174400-01 | WU, REEN | EFFECTORBIO, INC., CA | $300,000 | ZRG1 |
| 2023 | Conditional male lethal Anopheles stephensi line for the efficient manufacture of malaria vaccines1R43AI174393-01 | BILLINGSLEY, PETER F.EAPPEN, ABRAHAM GEEVARGHESE | SANARIA, INC., MD | $300,000 | ZRG1 |
| 2023 | A Novel Multi-Epitope-Based Universal Vaccine Against Multiple Coronavirus Variants of Concern1R43AI174383-01 | VAHED, HAWA | TECHIMMUNE, LLC, CA | $300,000 | ZRG1 |
| 2023 | Acoustic-anatomic modeling and development of a patient-specific wearable therapeutic ultrasound device for peripheral arterial disease1R43HL167492-01 | ELSTAD, JULIANA | VIBRATO MEDICAL, INC., CA | $300,000 | ZRG1 |
| 2023 | FimH-Targeting Antibody-Recruiting Molecules as Novel Drugs for Preventing Complicated Urinary Tract Infections1R43AI174482-01 | HIBBING, MICHAEL EINERMCGRANE, LAUREL | FIMBRION THERAPEUTICS, INC., MO | $300,000 | ZRG1 |
| 2023 | Advanced Pediatric Airway Trainer for Enhanced Clinical Education in Pediatric Critical Care1R43HD111155-01 | SRINIVAS, GIRISH | TDA RESEARCH, INC., CO | $300,000 | ZRG1 |
| 2023 | Double-Encapsulated mRNA Vaccine for COVID-191R43AI165352-01A1 | CASTOR, TREVOR P. | APHIOS CORPORATION, MA | $300,000 | ZRG1 |
| 2023 | Parametric design software for nanostructured CRISPR payloads1R43GM149023-01 | ARMENTROUT, STEVEN L | PARABON NANOLABS, INC., VA | $299,999 | ZRG1 |
| 2023 | Process development for manufacturing eCD4-Ig1R44AI170285-01A1 | ALPERT, MICHAEL DAVID | EMMUNE, INC, FL | $299,998 | ZRG1 |
| 2023 | Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities1R43AI174486-01 | HALTAUFDERHYDE, KIRK DONALD | EPIVAX, INC., RI | $299,917 | ZRG1 |
| 2023 | Stop pulmonary airleaks with a novel inhaled dry powder aerosol1R43HL165960-01A1 | BEVERLIN II, BRYCE | QUENCH MEDICAL, INC., MN | $299,838 | ZRG1 |
| 2023 | Development of a multi-RNA signature in blood towards a rapid diagnostic test to robustly distinguish patients with acute myocardial infarction1R43HL167483-01 | SWEENEY, TIMOTHY E | INFLAMMATIX, INC., CA | $299,762 | ZRG1 |
| 2023 | Ultra-low-temperature (6 K) static NMR-DNP for metalloproteins, proteins in cells, and materials1R43GM148111-01 | DOTY, FRANCIS DAVID | DOTY SCIENTIFIC, INC., SC | $299,649 | ZRG1 |
| 2023 | Bacteria and pathogen characterizations using outer membrane vesicles1R43AI174576-01 | FARIS, GREGORY W | NUMENTUS TECHNOLOGIES INC., CA | $298,794 | ZRG1 |
| 2023 | A Redesigning Existing Drugs against Indispensable Targets (ReEDIT) platform technology for discovery of novel drugs to treat fungal infections1R43AI170288-01A1 | PARENT, STEPHEN | KATHERA BIOSCIENCE INC., NJ | $298,530 | ZRG1 |
| 2023 | Development of BIO 300 as a novel treatment for idiopathic pulmonary fibrosis1R43HL167432-01 | KAYTOR, MICHAEL D | HUMANETICS CORPORATION, MN | $298,474 | ZRG1 |
| 2023 | A Vitamin K analog countermeasure for organophosphate poisoning1R43AI176434-01 | CHAN, SHERINE S | NEUROENE THERAPEUTICS INC, DC | $298,297 | ZRG1 |
| 2023 | A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures1R44AI175069-01 | EBETINO, FRANK H. | BIOVINC, LLC, CA | $296,779 | ZRG1 |
| 2023 | Stabilization of therapeutic microbes for inclusion in a liquid matrix for delivery to the intestines1R43GM146506-01A1 | ANSELMO, AARON C | VITAKEY, INC., DC | $295,924 | ZRG1 |
| 2023 | T-cell receptor mimic affinity reagent generation using an in vivo novel immunogen strategy1R43GM149009-01 | WEINER, MICHAEL P | ABBRATECH, INC., CT | $295,460 | ZRG1 |
| 2023 | Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism1R43NS130849-01 | BAND, PHILIP ARTHUR | CYTODEL, INC., NY | $295,365 | ZRG1 |
| 2023 | An Inhaled Microbiome-Targeted Biotherapeutic for Treatment of COPD1R44HL164156-01A1 | NICOLA, TEODORA | RESBIOTIC, INC., AL | $295,274 | ZRG1 |
| 2023 | Development of a tele-mentoring system integrated into an ultra-portable surgical microscope to treat cataract in underserved populations1R43EY034066-01A1 | MALTESE, MATTHEW RUDOLPH | X-BIOMEDICAL, INC., PA | $293,470 | ZRG1 |
| 2023 | Improved Patient Reported Outcomes (iPRO) -Sleep Diary: A Tool to Improve Sleep Assessment in Clinical Trials1R43HL167541-01 | BROOKS, JUSTIN | D-PRIME LLC, VA | $291,872 | ZRG1 |
| 2023 | Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections1R44AI170133-01A1 | GERSHBURG, EDWARD | RATIONAL VACCINES, INC., MA | $288,088 | ZRG1 |
| 2023 | STI NG Plus, a Swab to Answer Molecular Panel Test for Point of Care Diagnosis and Treatment Recommendation1R43AI174562-01 | DONG, SHOULIAN | AMPLIFIDX INC, MA | $286,775 | ZRG1 |
| 2023 | A recombinant elastin skin substitute for the treatment of burns1R43GM149096-01A1 | ROBERTS, STEFAN | INSOMA BIO, INC., NC | $282,373 | ZRG1 |
| 2023 | Developing a High-Flow Acoustofluidic Loading Platform for Research Cell Stabilization in the Anhydrous State1R43TR004327-01 | JANIS, BRETT R | DESICORP, INC., KY | $281,873 | ZRG1 |
| 2023 | First-in-class TREM-1 inhibitors for neovascular retinal diseases1R44EY034015-01A1 | SIGALOV, ALEXANDER B | SIGNABLOK, INC., MA | $278,127 | ZRG1 |
| 2023 | Microfluidic Cartridge for Point-of-Care Hematology Analysis1R43HL167435-01 | MABRY, KELLYROBLES, FRANCISCO E | CELLIA SCIENCE, INC., AR | $275,985 | ZRG1 |
| 2023 | The SE-Learn Online Professional Development Platform for Enhanced Social Emotional Learning with Students1R43MH135947-01 | DEROSIER, MELISSA E. | 3-C INSTITUTE FOR SOCIAL DEVELOPMENT, NC | $275,722 | ZRG1 |
| 2023 | Rapid and low-cost PFAS detection with advanced solid-state nanopore chips1R43ES034321-01A1 | XIA, ZEHUI | GOEPPERT, LLC, PA | $275,700 | ZRG1 |
| 2023 | Novel approaches for the treatment of autoimmune disease1R43AI174502-01 | KANNANGANAT SIDHARTHAN, SUNIL | ASTERO ERADO INC, TX | $275,213 | ZRG1 |
| 2023 | Simultaneous analysis of cell-borne and soluble biomarkers by high throughput acoustic flow cytometry1R43GM149072-01 | O'ROURKE, JOHN PETER | BENNUBIO INC, NM | $275,175 | ZRG1 |
| 2023 | Consumer-Therapist-Connector: Increasing Access to Quality Behavioral Healthcare1R43MH132156-01 | KRAUS, DAVID R. | OUTCOME REFERRALS INC, MA | $274,787 | ZRG1 |
| 2023 | PA TH2Caregiving: Data-Driven Digital Engagement to Assess and Address the Needs of Family Caregivers1R43NR020679-01 | VAUGHN, STEPHANIE ANN | PATH2CAREGIVING LLC, NC | $274,522 | ZRG1 |
| 2023 | Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.1R43AI174328-01 | GUO, HONGJIELIU, CHANG | ANTIGER THERAPEUTICS INC., MO | $272,503 | ZRG1 |
| 2023 | Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease1R43DK135153-01 | CHATZI, AIKATERININEGGERS, JASPER E | PROMAKHOS THERAPEUTICS INC., MA | $271,865 | ZRG1 |
| 2023 | Recombinant human CC10 protein for treatment and prevention of chronic lung allograft dysfunction1R43HL167372-01 | PILON, APRILE L | APCBIO INNOVATIONS, INC., MD | $260,664 | ZRG1 |
| 2023 | VisitBoost: A Home Visiting Enhancement to Reduce Harm for Families Affected by Substance Misuse1R43DA057785-01 | CIOFFI, CAMILLE CSMITH, DAVID RANDOLPH | OREGON RES BEHAVIORAL INTERVENTION STRAT, OR | $259,611 | ZRG1 |
| 2023 | Developing a Digital Training and Assessment Platform to Disseminate a Successful NIH-Supported College Preparation Model for Diversifying the U.S. Biomedical Workforce1R43GM149014-01 | HORNBECK, BETHANY | MOTHER COMMUNICATIONS CO., WV | $259,610 | ZRG1 |
| 2023 | Tele-Sox: A Tele-Medicine solution based on wearables and gamification to prevent Venous thromboembolism in Oncology Geriatric Patients1R43AG074888-01A1 | JOSHI, ROSHANAJAFI, BIJAN | STEXOLE LLC, TX | $259,600 | ZRG1 |
| 2023 | Portable Scaled Sample Preparation Device for Concentration and Recovery of Bacterial Contaminants1R43AI174492-01 | SU, XIAOLI | VIC FOUNDRY, INC., AR | $259,553 | ZRG1 |
| 2023 | Development, feasibility, and acceptability of Aim to Play, a user-friendly digital application for teacher skills training and physical education activities for K-2 elementary students1R43MD018245-01 | JOHNSON-SHELTON, DEBORAHRICCI, JEANETTEWESTLING, ERIKA | SAAVSUS, INC., OR | $259,552 | ZRG1 |
| 2023 | Virtual Reality Train the Trainer (VRT3)1R43GM149022-01 | CROSS, ERNEST VINCENTDUGGAN, DANIEL JLYNN, SPENCER | CHARLES RIVER ANALYTICS, INC., MA | $259,381 | ZRG1 |
| 2023 | The Development of CSD peptides for the therapeutic treatment of post-acute sequelae of COVID-19 (PACS)1R43HL167437-01 | MACKENZIE, BREANNE | LUNG THERAPEUTICS, INC., TX | $259,332 | ZRG1 |
| 2023 | Novel Peptide Immunomodulators for Treating Sepsis1R43AI174395-01 | AHMAD, SAIRA | ELDEC PHARMACEUTICALS, INC., NC | $259,121 | ZRG1 |
| 2023 | Development of a rapid screening test for the detection of dihydroanatoxin-a1R43ES034301-01A1 | FORD, LANCE P | ATTOGENE, TX | $259,002 | ZRG1 |
| 2023 | Multiplexed biosensor for personal wildfire exposure assessment1R43ES034322-01A1 | DU, DAN | DL ADV-TECH, LLC, WA | $258,999 | ZRG1 |
| 2023 | Development of a Nematode-Derived Drug to Treat Asthma1R43HL167369-01 | NGUYEN, HUNG | HOLOCLARA, INC., CA | $258,996 | ZRG1 |
| 2023 | Ceragenin-coated pedicle screws to tackle surgical-site infections.1R43AI174666-01 | BRUNNER, GLENN | N8 MEDICAL, INC., OH | $258,455 | ZRG1 |
| 2023 | High-throughput profiling of proteases with phage and arrays1R43AI174404-01 | KAY, BRIAN KENNETH | TANGO BIOSCIENCES, INC., IL | $256,776 | ZRG1 |
| 2023 | A Digital Health Technology to Prevent Family Violence and Improve Child Mental Health1R43MH132191-01 | HAZEN, CHRISTOPHERSTORMSHAK, ELIZABETH A | NORTHWEST PREVENTION SCIENCE INC, OR | $251,907 | ZRG1 |
| 2023 | Wearable Device and Digital Health Platform to Optimize Sleep During Pregnancy1R43HD111096-01 | DUGAN, STEVE R | SMART HUMAN DYNAMICS, INC., CA | $251,622 | ZRG1 |
| 2023 | Designing safe, potent, and cost-effective small peptide erythropoietin analogs1R43HL167440-01 | GINESTE, CYRILLE | COVENANT THERAPEUTICS, LLC, VA | $249,965 | ZRG1 |
| 2023 | Novel therapies for obesity- or diabetes-related lymphatic dysfunction1R43HL154880-01A1 | HU, MICKEY | LARIX BIOSCIENCE, LLC, CA | $245,728 | ZRG1 |
| 2023 | Kv2.1-Targeted First in Class Neuroprotective Therapeutic for Acute Ischemic Stroke1R43NS127620-01A1 | COLEMAN, JULIE H | CELDARA MEDICAL, LLC, NH | $231,974 | ZRG1 |
| 2023 | Development of a rapid, scalable, and deployable point-of-care blood volume diagnostic for monitoring postpartum and trauma-related hemorrhage1R43HL167475-01 | BUSSE, LAWRENCE J | QUANTIPORT, INC., OR | $231,308 | ZRG1 |
| 2023 | Development of A Novel Nanoparticle Biosensor for Rapid, Point-of-Care Sepsis Diagnosis and Risk Assessment1R43AI174456-01 | LIU, KE | NAMI DIAGNOSTICS LLC, IL | $224,079 | ZRG1 |
| 2023 | Developing an integrated pipeline for routine generation of orthogonal GPCR-targeting nanobodies1R43GM149069-01 | ZHOU, XICHUN | VITAN-BIOTECH, LLC, CO | $218,622 | ZRG1 |
| 2023 | Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems.1R43GM149031-01 | PEARLMAN, DAVID A | QUANTUM SIMULATION TECHNOLOGIES, INC., MA | $148,629 | ZRG1 |
| 2022 | A novel highly stable pancreatic enzyme replacement therapy to improve outcomes for patients with pancreatic insufficiency.1R44DK134212-01 | BAKER, SHENDAGALLOTTO, ROBERT | SYNSPIRA THERAPEUTICS, INC., MA | $1,796,643 | ZRG1 |
| 2022 | Advanced Nucleation Technologies for Membrane Protein Crystallization to Accelerate Structure-Based Drug Design for Substance Use Disorders2R44DA047146-02 | BOND, ANDREW H. | DENOVX, LLC, IL | $1,775,613 | ZRG1 |
| 2022 | Human Disease-Specific Induced Pluripotent Stem Cells For Preclinical Drug Testing and Drug Discovery1R44HL158281-01A1 · under PA-20-260 | BUI, LYNNE A | KHLORIS BIOSCIENCES, INC., CA | $1,728,439 | ZRG1 |
| 2022 | A Safe, Fast, and Cost-Effective System for Tissue Removal in Laparoscopic Hysterectomy and Other Minimally Invasive Surgery1R44HD105575-01A1 · under PA-20-260 | FRANCIS, DANIEL | CLARIA MEDICAL, INC., CA | $1,569,462 | ZRG1 |
| 2022 | Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease2R44NS107079-02A1 | EKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $1,499,923 | ZRG1 |
| 2022 | Development of gene replacement therapy for Sanfilippo Syndrome Type C1R44NS129393-01 | SINGAMSETTY, SRIKANTH | PHOENIX NEST, INC., NY | $1,495,610 | ZRG1 |
| 2022 | Retinal eye-tracking as a prognostic tool for traumatic brain injury and concussion2R44NS095090-02A1 | SHEEHY, CHRISTY KATHLEEN | C. LIGHT TECHNOLOGIES, INC., CA | $1,454,697 | ZRG1 |
| 2022 | Eliminating Interference from Autofluorescence in Flow Cytometry2R44GM131619-02A1 | VACCA, GIACOMO | KINETIC RIVER CORPORATION, CA | $1,441,830 | ZRG1 |
| 2022 | Development of a novel dual HIF-α inhibitor and inducer of ferroptosis for kidney cancer2R44CA217385-03A1 | LIPPERT, ROBERT | KUDA THERAPEUTICS, INC., UT | $1,425,000 | ZRG1 |
| 2022 | IND-Enabling Toxicology for a Novel Ca2+ Channel Therapeutic to Improve Outcomes Associated with Checkpoint Inhibitor Immunotherapy1R44CA268541-01A1 | GREENBERG, MILTON L | VIVREON BIOSCIENCES, LLC, CA | $1,371,030 | ZRG1 |
| 2022 | In-cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System2R44GM137728-02 | WEINBERGER, SCOT RANDY | GENNEXT TECHNOLOGIES, INC., CA | $1,334,584 | ZRG1 |
| 2022 | A reagent kit for spatial transcriptomic analysis1R44HG012532-01 | FAN, CHRISTINA | CURIO BIOSCIENCE INC., CA | $1,299,179 | ZRG1 |
| 2022 | Functional drug fingerprinting with all-optical electrophysiology2R44MH122052-03 | DELANEY-BUSCH, NATHANIEL MCREEHARWOOD, BENJAMIN NATHANIEL | Q-STATE BIOSCIENCES, INC., MA | $1,296,058 | ZRG1 |
| 2022 | Long-acting Stable Glucagons for Treatment of Hyperinsulinism2R44DK111304-05 | FLUDZINSKI, PAWEL | AMIDEBIO, LLC, CO | $1,287,693 | ZRG1 |
| 2022 | Continuation Application for the development of Integrated continuous and single-use (ICS) bioproduction platform (Phase IIB)2R44GM117682-04 · under PA-20-260 | SHINKAZH, OLEG | CHROMATAN CORPORATION, MA | $1,284,233 | ZRG1 |
| 2022 | DUCTUS ARTERIOSUS STENT TO IMPROVE CONGENITAL HEART DEFECT MORTALITY2R44HL158304-02 | TANG, BEVERLY | STARLIGHT CARDIOVASCULAR, INC., CA | $1,256,635 | ZRG1 |
| 2022 | A rapid microfluidic diagnostic assay for the measurement of Direct Oral Anticoagulants from patient whole blood2R44HL149480-02A1 | CUKER, ADAMKUNKEL, MARKROSSI, JASON M | FLOBIO, LLC, PA | $1,222,556 | ZRG1 |
| 2022 | Development of a Multi-species Vaccine for Prevention of Bacterial Otitis Media1R44DC019874-01 · under PA-20-260 | MCOSKER, CHARLES C. | CLARAMETYX BIOSCIENCE, INC., OH | $1,207,921 | ZRG1 |
| 2022 | Novel Sensor Integrated Proteome on Chip (SPOC) platform for evaluating kinetic parameters of protein interactions in high throughput1R44TR004297-01 | TAKULAPALLI, BHARATH | SPOC PROTEOMICS INC., AZ | $1,178,727 | ZRG1 |
| 2022 | Novel patient-derived 3D platform for detecting TDP-43 proteinopathy and associated biomarkers for ALS/FTD1R44NS124457-01A1 · under PA-20-260 | DE MAJO, MARTINAULLIAN, ERIK M | SYNAPTICURE, INC., IL | $1,171,621 | ZRG1 |
| 2022 | Preventing Neurovascular Matrix Degradation and Hemorrhage in Acute Ischemic Stroke2R44HL147676-02A1 | JEONG, SUN YONGREED, GUY L | TRANSLATIONAL SCIENCES, INC., AZ | $1,161,162 | ZRG1 |
| 2022 | Development of a potent and selective oral ENPP1 inhibitor for oncology1R44CA278144-01 | KAADIGE, MOHAN RAOSHARMA, SUNIL | STINGRAY THERAPEUTICS, INC., TX | $1,160,011 | ZRG1 |
| 2022 | Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections2R44HL147749-02 | REED, MATTHEW | NOB HILL THERAPEUTICS, INC., NM | $1,158,273 | ZRG1 |
| 2022 | A novel approach for prevention of Bronchopulmonary dysplasia in at-risk pre-term infants1R44HD107857-01A1 | ACHARYA, SUCHISMITA | AYUVIS RESEARCH, INC., TX | $1,109,134 | ZRG1 |
| 2022 | A Portable PET Insert System for Simultaneous TOF-PET and MR Brain Imaging2R44MH123253-03 | CHANG, CHENMING | PETCOIL, INC., CA | $1,106,983 | ZRG1 |
| 2022 | An Improved Robotic Electrophysiology Platform for Arrhythmia Ablation2R44HL147745-02A1 | CREIGHTON, FRANCIS MILTONFADDIS, MITCH | UNANDUP, LLC, MO | $1,103,426 | ZRG1 |
| 2022 | Cutaneous Phosphorylated Alpha-Synuclein for Detection of Prodromal Synucleinopathies1R44NS127696-01 | LEVINE, TODD | CND LIFE SCIENCES, INC., AZ | $1,092,613 | ZRG1 |
| 2022 | Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease1R44NS127671-01 | DIDSBURY, JOHN | T3D THERAPEUTICS, INC., NC | $1,088,768 | ZRG1 |
| 2022 | DataJoint SciOps: A Managed Service for Neuroscience Data Workflows1R44NS129492-01 | YATSENKO, DIMITRI | VATHES INC., TX | $1,084,634 | ZRG1 |
| 2022 | A Highly Multiplexed, Multiomic 3D Mouse Brain Map Using MALDI-IHC1R44MH132196-01 | LIM, MARK | AMBERGEN, INC, MA | $1,084,108 | ZRG1 |
| 2022 | Continuous liquid-liquid extractors for doubling of productivity and henhancement of batch based drug manufacturing2R44GM140701-02 | ADAMO, ANDREA | ZAIPUT FLOW TECHNOLOGIES LLC, MA | $1,080,331 | ZRG1 |
| 2022 | Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC1R44HL164314-01 | DAS, ANINDITASALLOUM, FADI NSWINDLEHURST, CATHY A | NOVOMEDIX, INC., CA | $1,062,913 | ZRG1 |
| 2022 | DNA 3.0: Development of a novel, efficient and cost-effective enzymatic process for synthesis of DNA oligonucleotides2R44HG010995-02 | ZIELER, HELGE | PRIMROSE BIO, INC., CA | $1,059,968 | ZRG1 |
| 2022 | STARLIGHT, The Next Generation X-ray Imaging Technology1R44CA268468-01 · under PA-20-260 | SILVER, ERIC | IMAGINE SCIENTIFIC, INC., MA | $1,057,480 | ZRG1 |
| 2022 | Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases2R44CA239989-02A1 | JAY, MICHAEL | NAMI THERAPEUTICS CORP., CT | $1,054,145 | ZRG1 |
| 2022 | Thermoacoustic Range Verification During Delivery of a Clinical Plan by a Synchrocyclotron: transition from research prototype to turnkey clinical device2R44CA243764-02A1 | PATCH, SARAH KATHRYN | ACOUSTIC RANGE ESTIMATES, LLC, IL | $1,050,635 | ZRG1 |
| 2022 | Direct detection and identification of antimicrobial resistance genes in bloodstream infections1R44AI172441-01 | SINGER, ALON | HELIXBIND, INC., MA | $1,050,000 | ZRG1 |
| 2022 | Novel, Non-hormonal Therapeutic for Endometriosis2R44HD100289-04 | BURNS, KATHERINE ANNEPETROSSIAN, TANYA CHRISTINEH | ENDOMET BIOSCIENCES, INC, CA | $1,049,997 | ZRG1 |
| 2022 | Plasma-Generated Hydroxyl Radicals for Analysis of Three-Dimensional Structures in Protein Therapeutics2R44GM134849-02 | CHOUDHURY, FARAZ | IMMUTO SCIENTIFIC, INC., WI | $1,037,792 | ZRG1 |
| 2022 | PERSEVERE-PEF: optimizing medical therapy saves lives in heart failure with preserved ejection fraction1R44HL162139-01 · under PA-20-260 | VOSKERICIAN, GABRIELA | OPTIMA INTEGRATED HEALTH, INC., CA | $1,034,876 | ZRG1 |
| 2022 | A molecular toolbox to accelerate drug development for histone lysine methylation regulators1R44TR004227-01 | BURG, JONATHAN MICHAELKEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $1,025,085 | ZRG1 |
| 2022 | Quantification of combinatorial epigenetic modifications using defined nucleosome standards2R44GM131560-02 | JOHNSTONE, ANDREA LYNNKEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $1,024,490 | ZRG1 |
| 2022 | Engineered super-affinity reagents for detection of histone post-translational modifications1R44GM145007-01 · under PA-20-260 | SUN, ZU-WEN | EPICYPHER, INC., NC | $1,024,329 | ZRG1 |
| 2022 | Long-acting injectable tacrolimus for chronic immunosuppression1R44AI170362-01A1 | SHAH, SARJANSMITH, THOMAS J. | AURITEC PHARMACEUTICALS, INC., CA | $1,024,014 | ZRG1 |
| 2022 | Reading workstation for clinical contrast echocardiography2R44HL152939-02 | SKLENAR, JIRI | NARNAR, LLC, OR | $1,023,511 | ZRG1 |
| 2022 | MammoCAT Advanced Full Field Digital Mammography System1R44CA268305-01A1 | BAMBOT, SHABBIR BAKIR | FISCHER IMAGING, INC., CO | $1,023,397 | ZRG1 |
| 2022 | IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus1R44AI167461-01 · under PA-20-260 | HUTCHINS, JEFF T | INHALON BIOPHARMA, INC., NC | $1,023,232 | ZRG1 |
| 2022 | Quantitative mapping of dynamic epigenetic states in rare and stimulated immune cells1R44AI167215-01A1 | KEOGH, MICHAEL-CHRISTOPHER | EPICYPHER, INC., NC | $1,022,665 | ZRG1 |
| 2022 | A Novel Immunologically Directed Probiotic for the Treatment of Type 1 Diabetes1R44DK134274-01 | FANGER, GARYFURLAN FREGUIA, CHRISTIAN | RISE THERAPEUTICS, LLC, MD | $1,021,316 | ZRG1 |
| 2022 | Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer1R44CA265547-01A1 | BELLAIL, ANITAHAO, CHUNHAI CHARLIELO, HO YIN | HB THERAPEUTICS, INC., IN | $1,019,583 | ZRG1 |
| 2022 | Clinical Decision Support for Assessing Pulmonary Embolism using Machine Learning2R44HL152825-02 · under PA-20-260 | KRAMER, KEVIN M. | MINNESOTA HEALTHSOLUTIONS CORPORATION, MN | $1,018,633 | ZRG1 |
| 2022 | Development of a Precision Medicine-based Diagnostic Tool for Membranous Nephropathy2R44DK130702-02 | LARSEN, CHRISTOPHER PSTOREY, AARON JOSEPH | NEPHROPATHOLOGY ASSOCIATES, AR | $1,018,450 | ZRG1 |
| 2022 | Comprehensive validation and commercial readiness of SpliceIO, a software platform for neoantigen discovery using RNA-seq data1R44CA265446-01A1 | AKERMAN, MARTINARUN, GAYATRI | ENVISAGENICS, INC., NY | $1,018,170 | ZRG1 |
| 2022 | A Web Service for Fragment-based Selectivity Analysis of Drug Leads2R44GM133284-02A1 | KULP III, JOHN LAURENCE | CONIFER POINT PHARMACEUTICALS, LLC, PA | $1,016,453 | ZRG1 |
| 2022 | Benchtop Q-Band Pulsed EPR Spectrometer for Intermolecular Distance Measurements2R44GM137640-02 | MALY, THORSTEN | BRIDGE 12 TECHNOLOGIES, INC., MA | $1,014,127 | ZRG1 |
| 2022 | Comprehensive Assessment of Cancer Immunotherapy Response2R44CA257253-02 | PERK, TIMOTHY | AIQ SOLUTIONS, INC., WI | $1,012,057 | ZRG1 |
| 2022 | Development of an oral analgesic with reduced liabilities1R44DA056336-01 | GEHLERT, DONALD RSCHMIDT, WILLIAM K | EPIODYNE, INC., CA | $1,011,134 | ZRG1 |
| 2022 | Phase IIB: Development of TruT Algorithm for Commercialization in Androgen Disorders2R44AG045011-04 | JASUJA, RAVI | FUNCTION PROMOTING THERAPIES, LLC, MA | $1,008,781 | ZRG1 |
| 2022 | Development of the Inspired Therapeutics NeoMate Mechanical Circulatory Support System for Neonates and Infants2R44HL144214-02 | DASSE, KURT A | INSPIRED THERAPEUTICS, LLC, VA | $1,002,565 | ZRG1 |
Showing the 200 most recent of 6,331 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.